GlassScriptPhysician profile
Nan Amanda Wang
NPI 1851788285
$1,084.14
in general payments reported to CMS, 2019-2025
20 companies · $453 in 2025
The $453 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.39 · 2020: $106 · 2021: $13.21 · 2023: $264 · 2024: $166 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.21 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $212.82 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $146.99 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $109.39 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.81 | 2019-2025 | |
| Evofem Biosciences, INC. | $68.46 | 2024-2025 | Phexxi, Solosec, Phexx |
| Abbvie INC. | $58.82 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $56.47 | 2020-2023 | Slynd |
| Biogen, INC. | $54.37 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $41.59 | 2019-2020 | |
| Dexcom, INC. | $35.66 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $31.30 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $25.03 | 2019-2020 | |
| Millicent US INC | $24.14 | 2024 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $22.08 | 2025 | Myfembree |
| Coopersurgical, INC. | $21.71 | 2025 | Endosee, Paragard T 380a |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $16.42 | 2025 | Acessa Provu System, Novasure |
| Novo Nordisk INC | $16.05 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.66 | 2019 | |
| Lupin INC. | $11.36 | 2020 | |
| Mission Pharmacal Company | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.